ICA (10–120 mg/kg, po for 1–3 months) positively modulated multiple targets associated with Aβ pathways and thus, may be beneficial in attenuating the level of Aβ in the VaD or AD brain by decreasing the production of Aβ (via downregulation of beta-site APP cleaving enzyme 1 (BACE1) and upregulation of ADAM10) and by increasing the degradation of Aβ (upregulation of IDE). This evidence concerns the gene BACE1 and Alzheimer disease.